In contrast, enrichment scores for basal differentiation, EMT (epithelial-mesenchymal transition) differentiation, and immune differentiation were lower in the high-GATA3 group; a luminal subtype of BLCA with high GATA3 predicted a weaker response to ICB therapy. The gene discussed is GATA3; the disease is bladder transitional cell carcinoma.